Bloomberg TV: Hassabis thinks Alphabet subsidiary Isomorphic Labs could be a $100 billion company.
BLOOMBERG TV. And when we think of RNA, a lot of us will think of RNA and the successful vaccines against Covid. What are the potential adjustments or the implications for RNA vaccines from this technology?
HASSABIS: Yeah, I think this is a really interesting space that we can now get into. I think with these with AlphaFold 3 and the new capabilities it has in biologics, maybe antibody antibodies, this sort of new space beyond small molecules. And we think there’s great advances to be made there as well as with chemical compounds and small molecules. So I think it sort of opens up the type of opportunities that we can tackle.
Google DeepMind CEO and Co-Founder Demis Hassabis speaks with Bloomberg’s Tom Mackenzie about the latest version of the company’s AlphaFold AI system (AlphaFold 3), intended to tackle problems in biology including disease protection and treatment. Hassabis also discusses the hype cycle in AI, as well as the timeframe for AI-developed drugs and why he thinks Alphabet subsidiary Isomorphic Labs could be a $100 billion company. 00:00 – Intro 00:32 – AlphaFold 3, understanding dynamic picture of protein interactions 01:28 – Timeline for AI derived drugs. Partnerships with Eli Lilly and Novartis 02:03 – Isomorphic Labs, drug discovery 02:05 – Potential for mRNA vaccines 03:25 – Competitive threat from OpenAI 04:24 – Sustainability of AI 06:10 – Rationalization in AI sector, more closures and failures 07:14 – UK AI safety summit 08:47 – Big election year – are Labour as invested in AI? 09:20 – What are the big things coming this year? 10:31 – Isomorphic Labs, under pressure to commercialize? 12:20 – What keeps you up at night? ——– More on Bloomberg Television and Markets